List view / Grid view
28 May 2015 | By Victoria White
Johnson & Johnson has accepted the 1 March 2015 binding offer from Cardinal Health to acquire its Cordis business for an approximate value of $2 billion...
7 May 2015 | By Victoria White
J&J has announced a first-of-its-kind partnership that enlists a third party to review compassionate use requests made for investigational medicines...
Now in its fifth year, the Productive Innovation Index (PII) celebrates the top 30 pharmaceutical companies most effective at developing and commercialising new medicines – bringing innovations to market successfully.
12 December 2014 | By Johnson & Johnson
Memorandum of Understanding signed to address the global health threat of antibiotic-resistant bacteria...
29 July 2014 | By Johnson & Johnson
The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for IMBRUVICA® (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.1 The FDA also approved IMBRUVICA for CLL patients with del 17p,1 a genetic…
1 July 2014 | By Johnson & Johnson
Johnson & Johnson announced that it has completed the divestiture of its Ortho-Clinical Diagnostics business to The Carlyle Group for approximately $4 billion...
25 June 2014 | By Johnson & Johnson
Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc. announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute...
23 June 2014 | By Johnson & Johnson
Johnson & Johnson announced that its Board of Directors has appointed D. Scott Davis, Chief Executive Officer and Chairman of United Parcel Service, Inc. as a Director of Johnson & Johnson...
30 April 2014 | By Johnson & Johnson
Johnson & Johnson announced that its affiliate Janssen Pharmaceutica NV has entered into a novel collaboration with the Stichting International Dispensary Association...
15 April 2014 | By Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting…
In this Process Analytical Technology (PAT) In-Depth Focus: Presenting a rational approach to QbD-based pharmaceutical development: A roller compaction case study, PAT for pharmaceutical spray drying, PAT Roundtable, Show Preview: IFPAC® 2014...
4 November 2013 | By Johnson & Johnson
The resolution includes total settlement amounts of approximately $2 billion to the federal government...
24 October 2013 | By Johnson & Johnson
Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration voted unanimously to recommend approval of the investigational protease inhibitor simeprevir...
18 October 2013 | By Johnson & Johnson
Dr. McClellan has more than two decades of public service and academic research experience...
3 October 2013 | By Johnson & Johnson
Collaborations announced between regional innovators and Johnson & Johnson family of companies...
